Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - Medicine, 2018 - journals.lww.com
… was consistent across various subgroups, the pooled efficacies for PFS, OS, and ORR were
… A phase III RCT compared gefitinib and erlotinib in EGFR mutation-positive NSCLC and …
… A phase III RCT compared gefitinib and erlotinib in EGFR mutation-positive NSCLC and …
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
P Krawczyk, DM Kowalski, R Ramlau… - Oncology …, 2017 - spandidos-publications.com
… routinely used to treat non-small cell lung cancer (NSCLC) in patients with common activating
mutations of the EGFR gene. The aim of the study was to compare the efficacies of EGFR‑…
mutations of the EGFR gene. The aim of the study was to compare the efficacies of EGFR‑…
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
…, Hokkaido Lung Cancer Clinical Study Group - Cancer chemotherapy …, 2017 - Springer
… Erlotinib might have also been recommended as third-line in the 2009 ASCO … efficacy
in patients who received erlotinib as third-line compared with those who received erlotinib as …
in patients who received erlotinib as third-line compared with those who received erlotinib as …
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC cancer, 2018 - Springer
… gefitinib and erlotinib have both been proven effective for treating advanced non–small cell
lung cancer … compare their efficacy and safety in treating advanced NSCLC in this population. …
lung cancer … compare their efficacy and safety in treating advanced NSCLC in this population. …
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor …
… IIIb-IV non-small cell lung cancer harboring EGFR classical … the efficacy of gefitinib/erlotinib
and afatinib in patients with … - or third-line treatment, but most patients received EGFR-TKI …
and afatinib in patients with … - or third-line treatment, but most patients received EGFR-TKI …
Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis
Y Liu, Y Zhang, G Feng, Q Niu… - … and therapeutic …, 2017 - spandidos-publications.com
… reported that, compared with gefitinib, erlotinib possesses an … reported that gefitinib and
erlotinib have similar efficacies (12… toxicity compared with gefitinib for the treatment of advanced …
erlotinib have similar efficacies (12… toxicity compared with gefitinib for the treatment of advanced …
… and safety of gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib followed by second-line chemotherapy: a …
Y Song, YL Wu, LJ Cao, JH Chen, ZY Ma… - American Journal of …, 2019 - journals.lww.com
… care for advanced non–small cell lung cancer (NSCLC) … 7.7 mo) was observed in
T790M-negative patients compared … of erlotinib for patients with stable disease on prior gefitinib …
T790M-negative patients compared … of erlotinib for patients with stable disease on prior gefitinib …
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer …
JW Neal, SE Dahlberg, HA Wakelee, SC Aisner… - The lancet …, 2016 - thelancet.com
… We compared the efficacy of cabozantinib alone or in combination with … in the second-line
and third-line setting. We did this trial to directly compare the efficacy of erlotinib with …
and third-line setting. We did this trial to directly compare the efficacy of erlotinib with …
Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …
B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - jamanetwork.com
… ’s efficacy in advanced non–small cell lung cancer (NSCLC). … in the third-line or beyond
setting that compared a multitarget … TKIs—such as gefitinib, erlotinib hydrochloride, and afatinib …
setting that compared a multitarget … TKIs—such as gefitinib, erlotinib hydrochloride, and afatinib …
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
B Han, K Li, Y Zhao, B Li, Y Cheng, J Zhou, Y Lu… - … journal of cancer, 2018 - nature.com
… and efficacy of third-line anlotinib for patients with refractory … erlotinib or gefitinib and have
a PS of 0–3, the efficacy of this … in NSCLC, although direct comparisons of AEs with other …
a PS of 0–3, the efficacy of this … in NSCLC, although direct comparisons of AEs with other …